Scholarlink

Background/aim <p>In our study, we aimed to investigate the effect of PPI use on peritonitis, and hepatic encephalopathy in patients with liver cirrhosis.</p> Materials and methods <p>Our study was conducted on 220 patients. Patients with cirrhosis were divided into two groups PPI users and non-users. After the patients who did not use PPIs in their records were informed that they should not use PPIs in the future, both groups were followed up for three more years. 129 (58.6%) of the patients were PPI users and 91 (41.4%) of the patients were not PPI users. At the end of three years, these two groups were compared in terms of peritonitis. and encephalopathy.</p> Results <p>The presence of encephalopathy was compared with PPI use status. Encephalopathy was present in 20 (16.2%) of PPI users, while 12 (13.2%) of non-PPI users had encephalopathy. No significant difference was found between the groups (p=0.230). When the presence of peritonitis in the patients was analyzed, peritonitis was found in 30 (23.7%) of the patients using PPIs, while 16 (17.6%) of the patients not using PPIs had peritonitis. There was no statistically significant difference between the groups (p=0.103).</p> Conclusion <p>In our study, there was no statistically significant association between PPI use, peritonitis, and encephalopathy in patients with cirrhosis. It may be possible that this association may emerge in patients with decompensated cirrhosis and longer follow-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of the use of proton pump inhibitors (PPI) on complications in patients with cirrhosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Halil Atasoy,
  • Arzu Levent

摘要

Background/aim

In our study, we aimed to investigate the effect of PPI use on peritonitis, and hepatic encephalopathy in patients with liver cirrhosis.

Materials and methods

Our study was conducted on 220 patients. Patients with cirrhosis were divided into two groups PPI users and non-users. After the patients who did not use PPIs in their records were informed that they should not use PPIs in the future, both groups were followed up for three more years. 129 (58.6%) of the patients were PPI users and 91 (41.4%) of the patients were not PPI users. At the end of three years, these two groups were compared in terms of peritonitis. and encephalopathy.

Results

The presence of encephalopathy was compared with PPI use status. Encephalopathy was present in 20 (16.2%) of PPI users, while 12 (13.2%) of non-PPI users had encephalopathy. No significant difference was found between the groups (p=0.230). When the presence of peritonitis in the patients was analyzed, peritonitis was found in 30 (23.7%) of the patients using PPIs, while 16 (17.6%) of the patients not using PPIs had peritonitis. There was no statistically significant difference between the groups (p=0.103).

Conclusion

In our study, there was no statistically significant association between PPI use, peritonitis, and encephalopathy in patients with cirrhosis. It may be possible that this association may emerge in patients with decompensated cirrhosis and longer follow-up.